ReviewAntibiotics (Basel, Switzerland)2026
Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.
Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesCarbapenem-resistant Enterobacterales (CRE) infections represent a critical global health threat with limited therapeutic options and high mortality rates. Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations have emerged, but their comparative impact on survival versus best available therapy (BAT) remains to be comprehensively assessed. This systematic review evaluates the mechanistic, microbiological, and genetic factors affecting treatment success.
methodsRandomized controlled trials (RCTs) and observational reports published up to December 2025 were included. An intensive search strategy was conducted through PubMed/Medline, Embase, Scopus, Cochrane, and Web of Science databases. The trials compared novel BL/BLI agents ceftazidime/avibactam (CAZ-AVI), Meropenem/Vaborbactam (MER-VABO), and Imipenem/Cilastatin/Relebactam (IPM-CIL-REL) to BAT for CRE infections that reported all-cause mortality in adult hospitalized patients (≥18 years). Data retrieval included carbapenemase types, resistance mechanisms, and minimum inhibitory concentrations (MICs). Risk ratios (RRs), heterogeneity (I
resultsThe meta-analysis included nine primary studies (six RCTs and three observational cohorts) with 2892 CRE-infected patients. Compared to BAT, BL/BLI combinations significantly reduced mortality by 27% (pooled RR = 0.73; 95% Confidence Intervals (CI): 0.59-0.9;
conclusionsInnovative BL/BLI combinations lower all-cause mortality compared to BAT. This effect is extremely reliant on the comparator regimen composition, the specific BL/BLI drug, and the underlying resistance mechanism. These data support a precision medicine approach guided by rapid molecular diagnostics. These findings underscore the urgent need for novel agents against MBL-producing strains, including the recently approved aztreonam-avibactam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.